Morgans cuts target to AUD 0.40 for Healius stock

Published on 10/05/2026 at 11:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Healius agreed to sell Agilex for AUD 160 million on September 25, 2026. Healius stock costs EUR 0.25 on October 5, 2026 after EUR 0.25.

Healius, AU0000033359, Illustration mit AI erstellt.

Morgans lowered its Healius target from AUD 0.43 to AUD 0.40 on October 5, 2026, while retaining its Hold rating, FNArena reports. Healius stock was at EUR 0.25 at Lang & Schwarz on October 5, 2026 at 11:34 a.m. CEST, unchanged from the EUR 0.25 prior close.

Agilex sale resets the portfolio

According to Yahoo Finance on September 25, 2026, Healius signed a binding agreement to sell Agilex Biolabs to a Novotech unit for an enterprise value of AUD 160.00 million.

The transaction is expected to generate AUD 155.00 million in cash after separation and transaction costs, with completion targeted for the second half of fiscal 2027 after regulatory approvals. That cash would move Healius from AUD 32.80 million of net debt at the end of fiscal 2026 to a net cash position, according to the same Yahoo Finance report.

FY2026 earnings show the tradeoff

Healius delivered underlying revenue of AUD 1.37 billion in fiscal 2026, up 2.10 percent from the prior year, while underlying EBITDA rose 8.10 percent to AUD 258.60 million. Underlying EBIT increased to AUD 30.20 million from AUD 17.10 million in fiscal 2025, according to the Yahoo Finance transcript.

Agilex contributed AUD 43.60 million of revenue and AUD 6.40 million of EBIT in fiscal 2026. The divestment therefore removes a faster-growing unit, while leaving Healius with its core pathology business and a planned cash buffer for capital allocation.

Healius describes pathology as its central operating platform and says one in every three pathology samples in Australia is tested in its laboratories, according to its investor overview. The key comparison is operational: fiscal 2026 revenue grew 2.10 percent, while EBIT expanded by AUD 13.10 million, indicating that cost control contributed more than volume growth to the improvement.

Analysts weigh cash against scale

FNArena says Macquarie retained a Neutral rating and reduced its target by AUD 0.03 to AUD 0.43, citing pathology wage pressures, subdued general-practitioner attendances and the pace of margin recovery. Morgans instead highlighted lower equity-raising risk from the Agilex sale while keeping Hold.

At EUR 0.25, Healius stock has a market capitalization of AUD 294.10 million and a 52-week range of AUD 0.30 to AUD 1.07 as of October 5, 2026. The valuation remains tied to whether the sale proceeds can strengthen the balance sheet while the pathology business improves profitability.

Healius stock holds at EUR 0.25

Healius stock was trading at EUR 0.25 at Lang & Schwarz on October 5, 2026 at 11:34 a.m. CEST, unchanged at 0.00 percent versus the Lang & Schwarz prior close of EUR 0.25 on October 2, 2026.